Journal article
Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial
S Siva, D Pham, T Kron, M Bressel, J Lam, TH Tan, B Chesson, M Shaw, S Chander, S Gill, NR Brook, N Lawrentschuk, DG Murphy, F Foroudi
BJU International | WILEY | Published : 2017
DOI: 10.1111/bju.13811
Abstract
Objective: To assess the feasibility and safety of stereotactic ablative body radiotherapy (SABR) for renal cell carcinoma (RCC) in patients unsuitable for surgery. Secondary objectives were to assess oncological and functional outcomes. Materials and Methods: This was a prospective interventional clinical trial with institutional ethics board approval. Inoperable patients were enrolled, after multidisciplinary consensus, for intervention with informed consent. Tumour response was defined using Response Evaluation Criteria In Solid Tumors v1.1. Toxicities were recorded using Common Terminology Criteria for Adverse Events v4.0. Time-to-event outcomes were described using the Kaplan–Meier meth..
View full abstractGrants
Funding Acknowledgements
This study was supported by a CASS Science and Medicine grant SM/11/3784, and the Royal Australia and New Zealand College of Radiation Oncology / Ferring Pharmaceutical Fellowship Award. We thank Mr Andrew Lim for his assistance.